metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Benefits of SGLT2 inhibitors combining with renin–angiotensin-system blockers ...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Benefits of SGLT2 inhibitors combining with renin–angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis
Beneficios de los inhibidores de SGLT2 combinados con bloqueadores del sistema renina-angiotensina en los resultados cardiovasculares de los pacientes con enfermedad renal crónica: una revisión sistémica y un metaanálisis
Ting Liua,1, Rui Lib,1, Xiaoxia Wangb,1, Xingxing Gaob, Xiaodong Zhanga,
Corresponding author
zxdspl@163.com

Corresponding author.
a Department of Nephrology, The First Hospital of Shanxi Medical University, Taiyuan, China
b Shanxi Medical University, Taiyuan, China
Read
28
Times
was read the article
22
Total PDF
6
Total HTML
Share statistics
 array:24 [
  "pii" => "S0025775321006473"
  "issn" => "00257753"
  "doi" => "10.1016/j.medcli.2021.09.031"
  "estado" => "S300"
  "fechaPublicacion" => "2022-07-22"
  "aid" => "5848"
  "copyright" => "Elsevier España, S.L.U.. All rights reserved"
  "copyrightAnyo" => "2021"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Med Clin. 2022;159:65-72"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S2387020622003151"
      "issn" => "23870206"
      "doi" => "10.1016/j.medcle.2021.09.027"
      "estado" => "S300"
      "fechaPublicacion" => "2022-07-22"
      "aid" => "5848"
      "copyright" => "Elsevier España, S.L.U."
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Med Clin. 2022;159:65-72"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
        "titulo" => "Benefits of SGLT2 inhibitors combining with renin&#8211;angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients&#58; A systemic review and meta-analysis"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "65"
            "paginaFinal" => "72"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Beneficios de los inhibidores de SGLT2 combinados con bloqueadores del sistema renina-angiotensina en los resultados cardiovasculares de los pacientes con enfermedad renal cr&#243;nica&#58; una revisi&#243;n sist&#233;mica y un metaan&#225;lisis"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0040"
            "etiqueta" => "Fig&#46; 4"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr4.jpeg"
                "Alto" => 1614
                "Ancho" => 2175
                "Tamanyo" => 175853
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Forest plot of meta-analyses comparing 24hUAE and eGFR of combination therapy with SGLT2 inhibitors and RAS blockers versus placebo&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ting Liu, Rui Li, Xiaoxia Wang, Xingxing Gao, Xiaodong Zhang"
            "autores" => array:5 [
              0 => array:2 [
                "nombre" => "Ting"
                "apellidos" => "Liu"
              ]
              1 => array:2 [
                "nombre" => "Rui"
                "apellidos" => "Li"
              ]
              2 => array:2 [
                "nombre" => "Xiaoxia"
                "apellidos" => "Wang"
              ]
              3 => array:2 [
                "nombre" => "Xingxing"
                "apellidos" => "Gao"
              ]
              4 => array:2 [
                "nombre" => "Xiaodong"
                "apellidos" => "Zhang"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S0025775321006473"
          "doi" => "10.1016/j.medcli.2021.09.031"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321006473?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020622003151?idApp=UINPBA00004N"
      "url" => "/23870206/0000015900000002/v1_202207200641/S2387020622003151/v1_202207200641/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0025775321006321"
    "issn" => "00257753"
    "doi" => "10.1016/j.medcli.2021.09.023"
    "estado" => "S300"
    "fechaPublicacion" => "2022-07-22"
    "aid" => "5833"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Med Clin. 2022;159:73-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
      "titulo" => "Influencia de las comorbilidades en la intensidad del dolor en los pacientes con lumbalgia cr&#243;nica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "73"
          "paginaFinal" => "77"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Influence of comorbidities on pain intensity in patients with chronic low back pain"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Martha Cristina Melo Cruz, Maria Teresa Santeularia Verges, Carme Rius Llorens, Ignasi J&#46; Gich Saladich, Elena Catal&#224; Puigb&#243;"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Martha Cristina"
              "apellidos" => "Melo Cruz"
            ]
            1 => array:2 [
              "nombre" => "Maria Teresa"
              "apellidos" => "Santeularia Verges"
            ]
            2 => array:2 [
              "nombre" => "Carme"
              "apellidos" => "Rius Llorens"
            ]
            3 => array:2 [
              "nombre" => "Ignasi J&#46;"
              "apellidos" => "Gich Saladich"
            ]
            4 => array:2 [
              "nombre" => "Elena"
              "apellidos" => "Catal&#224; Puigb&#243;"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2387020622003072"
        "doi" => "10.1016/j.medcle.2021.09.026"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020622003072?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321006321?idApp=UINPBA00004N"
    "url" => "/00257753/0000015900000002/v1_202207080542/S0025775321006321/v1_202207080542/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0025775321005285"
    "issn" => "00257753"
    "doi" => "10.1016/j.medcli.2021.08.003"
    "estado" => "S300"
    "fechaPublicacion" => "2022-07-22"
    "aid" => "5808"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Med Clin. 2022;159:59-64"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "High-resolution computed tomography &#40;HRCT&#41; analysis in anti-synthase antibody syndrome with organizing pneumonia"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "59"
          "paginaFinal" => "64"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "An&#225;lisis por tomograf&#237;a computarizada de alta resoluci&#243;n &#40;TCAR&#41; del s&#237;ndrome de anticuerpos antisint&#233;ticos con un patr&#243;n de neumon&#237;a organizada"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1456
              "Ancho" => 2083
              "Tamanyo" => 116035
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">The FVC&#37; has a linear relationship with mean lung attenuation of the extracted whole lung volume with attenuation values of the poorly aerated and fibrosis&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Xueren Li, Qi Wu, Shouchun Peng, Huarui Zhang, Yuhua Zhang"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Xueren"
              "apellidos" => "Li"
            ]
            1 => array:2 [
              "nombre" => "Qi"
              "apellidos" => "Wu"
            ]
            2 => array:2 [
              "nombre" => "Shouchun"
              "apellidos" => "Peng"
            ]
            3 => array:2 [
              "nombre" => "Huarui"
              "apellidos" => "Zhang"
            ]
            4 => array:2 [
              "nombre" => "Yuhua"
              "apellidos" => "Zhang"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321005285?idApp=UINPBA00004N"
    "url" => "/00257753/0000015900000002/v1_202207080542/S0025775321005285/v1_202207080542/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Benefits of SGLT2 inhibitors combining with renin&#8211;angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients&#58; A systemic review and meta-analysis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "65"
        "paginaFinal" => "72"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Ting Liu, Rui Li, Xiaoxia Wang, Xingxing Gao, Xiaodong Zhang"
        "autores" => array:5 [
          0 => array:3 [
            "nombre" => "Ting"
            "apellidos" => "Liu"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">1</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Rui"
            "apellidos" => "Li"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">1</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Xiaoxia"
            "apellidos" => "Wang"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">1</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Xingxing"
            "apellidos" => "Gao"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "Xiaodong"
            "apellidos" => "Zhang"
            "email" => array:1 [
              0 => "zxdspl@163.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Department of Nephrology&#44; The First Hospital of Shanxi Medical University&#44; Taiyuan&#44; China"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Shanxi Medical University&#44; Taiyuan&#44; China"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Beneficios de los inhibidores de SGLT2 combinados con bloqueadores del sistema renina-angiotensina en los resultados cardiovasculares de los pacientes con enfermedad renal cr&#243;nica&#58; una revisi&#243;n sist&#233;mica y un metaan&#225;lisis"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0035"
        "etiqueta" => "Fig&#46; 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1860
            "Ancho" => 2175
            "Tamanyo" => 244414
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Forest plot of meta-analyses comparing renal outcomes of combination therapy with SGLT2 inhibitors and RAS blockers versus placebo&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic kidney disease &#40;CKD&#41; affects 8&#8211;16&#37; of the global population and is associated with a high morbidity and mortality rates&#46;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">1</span></a> CKD has also been found to play a crucial role in the development of other diseases&#44; and in all-cause and cardiovascular mortality&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">2</span></a> The risk of such a death increases exponentially as kidney function deteriorates&#46;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">3</span></a> Therefore&#44; it is important to prevent CKD progression&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Renin&#8211;angiotensin-system &#40;RAS&#41; blockers have been shown to be cardioprotective because of their antihypertensive and proteinuric effects&#46;<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">4&#44;5</span></a> Therefore&#44; clinical practice guidelines recommend using RAS blockers for treating CKD or diabetic nephropathy&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">2</span></a> However&#44; the risk of disease progression in CKD patients remains high even after the use of RAS blockers&#44; and clinicians look forward to new therapeutic approaches&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Sodium-glucose cotransporter-2 &#40;SGLT2&#41; inhibitors are a new class of antidiabetic drugs&#44; which inhibit the reabsorption of glucose in the proximal tubules of the kidney&#44; thus exerting a hypoglycemic effect&#46;<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">6&#44;7</span></a> Several large randomized controlled trials &#40;RCTs&#41;&#44; such as CREDENCE<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">8</span></a> and EMPA-REG&#44;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">9</span></a> have confirmed the cardiorenal protective effect of SGLT2 inhibitors&#44; especially in diabetes patients with CKD&#46; Furthermore&#44; the 2020 KDIGO guidelines recommend using SGLT2 inhibitors in CKD patients who have diabetes&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">10</span></a> An increasing number of studies have suggested that the renoprotective effect of SGLT2 inhibitors may be independent of their hypoglycemic effect&#46;<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">11</span></a> The latest results of DAPA-CKD are exciting and provide evidence for the benefits of using SGLT2 inhibitors for the treatment of CKD&#46;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">12</span></a> Studies have demonstrated that both SGLT2 inhibitors and RAS blockers can reduce glomerular hyperfiltration&#44;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">13</span></a> and we found that RAS blockers are often used as background therapy in some RCTs reporting on SGLT2 inhibitors therapy for CKD&#46; Thus&#44; it is necessary to explore the significance of this combination for CKD treatment&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methods</span><p id="par0020" class="elsevierStylePara elsevierViewall">This study was pre-registered on PROSPERO &#40;CRD42020218337&#41; and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement &#40;PRISMA&#41;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">14</span></a> and MOOSE&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">15</span></a></p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Search strategy</span><p id="par0025" class="elsevierStylePara elsevierViewall">We searched Embase&#44; PubMed&#44; Web of Science and Cochrane Library using a combination of subject terms and free words&#46; The search terms included &#8220;renal insufficiency&#44; chronic kidney insufficiency&#44; sodium-glucose co-transporter 2 inhibitors&#44; sodium glucose transporter 2 inhibitors&#44; canagliflozin&#44; empagliflozin&#44; dapagliflozin&#44; tofogliflozin&#44; ipragliflozin&#44; luseogliflozin&#8221;&#44;and the search was conducted from the time the database was established to December 2020&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Inclusion and exclusion criteria</span><p id="par0030" class="elsevierStylePara elsevierViewall">Inclusion criteria&#58; &#40;1&#41; age<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>18 years and a precise diagnosis of CKD with eGFR<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#44; with or without diabetes&#59; &#40;2&#41; intervention group treated with SGLT2 inhibitors and the control group treated with placebo&#59; with both groups being treated with RAS blockers as background therapy&#59; &#40;3&#41; study outcome measures including the impact on renal and cardiovascular outcomes&#44; 24-h urinary albumin excretion rate &#40;24hUAE&#41;&#44; and estimated glomerular filtration rate &#40;eGFR&#41;&#59; and &#40;4&#41; RCTs&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Exclusion criteria&#58; &#40;1&#41; study types such as reviews&#44; conference abstracts&#44; incomplete end indicators&#44; and unpublished articles&#59; &#40;2&#41; the intervention or control group not treated with RAS blockers as background therapy or the study subjects not receiving complete RAS blocker background therapy&#59; and &#40;3&#41; previous severe heart or kidney disease in the subjects &#40;eGFR<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#44; severe heart failure&#44; angina&#44; myocardial infarction or stroke occurring within 6 months before enrollment in the trial&#41;&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Literature screening and data extraction</span><p id="par0040" class="elsevierStylePara elsevierViewall">The retrieved literature was first deduplicated using the EndNote software and then manually deduplicated&#46; After excluding duplicates&#44; we browsed the titles and abstracts to exclude irrelevant literature&#59; subsequently&#44; we scanned full texts to determine the final inclusion according to the inclusion and exclusion criteria&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">We read the final included literature and extracted the following primary data&#58; first author&#44; year&#44; study population&#44; gender composition&#44; mean age&#44; GFR&#44; sample size&#44; and intervention and follow-up duration&#46; The processes were independently performed by two researchers&#44; and any disputes arising during the process were coordinated and resolved by a third researcher&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Quality assessment</span><p id="par0050" class="elsevierStylePara elsevierViewall">The final included literature was evaluated for quality using the Cochrane Collaboration &#8220;risk of bias&#8221; assessment tool&#46; The evaluation items included the following&#58; &#40;1&#41; random sequences generation&#59; &#40;2&#41; allocation concealment&#59; &#40;3&#41; blinding of participants and personnel&#59; &#40;4&#41; blinding of outcome assessment&#59; &#40;5&#41; incomplete outcome data&#59; &#40;6&#41; selective reporting&#59; and &#40;7&#41; other bias&#46; Each assessment item was classified as high risk&#44; low risk&#44; or unclear&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">We statistically analyzed the data using the metan command in Stata software 14&#46;0&#44; and calculated the study outcome measures using the inverse variance method&#46; Continuous variables were expressed as weighted mean differences &#40;WMDs&#41; or standardized mean differences &#40;SMDs&#41; and 95&#37; confidence interval &#40;95&#37; CI&#41;&#46; Dichotomous variables were expressed as relative risk &#40;RR&#41; and 95&#37; CI&#44; and inter-study heterogeneity was expressed as <span class="elsevierStyleItalic">I</span><span class="elsevierStyleSup">2</span> and <span class="elsevierStyleItalic">p</span> values&#46; <span class="elsevierStyleItalic">I</span><span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>50&#37; or <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;1 indicated evident heterogeneity between studies&#44; and the random-effects model was used and further subgroup analysis was conducted to find the source of heterogeneity&#59; <span class="elsevierStyleItalic">I</span><span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>50&#37; or <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>0&#46;1 indicated that the heterogeneity between studies is acceptable&#44; and the fixed-effects model was used for analysis in this case&#46; The combined effect measure was statistically significant at <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;05&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Trials sequential analysis &#40;TSA&#41;</span><p id="par0060" class="elsevierStylePara elsevierViewall">In a small sample trial&#44; interim analyses cause false positive or false negative results&#44; implying an increased risk of type I errors or type II errors&#46; In particular&#44; in a meta-analysis that included small samples of trials&#44; the rate of random error is more significant&#46; Therefore&#44; to avoid an increase of random error&#44; we performed the TSA by TSA software to estimate the minimum sample size required to obtain the outcomes of statistical significance for the intervention and control group &#40;<a href="https://www.ctu.dk/tsa">https&#58;&#47;&#47;www&#46;ctu&#46;dk&#47;tsa</a>&#41;&#46; We set the risk of type I error at an overall 5&#37;&#44; being the standard in most meta-analyses&#44; to obtain the traditional boundary and the TSA threshold value&#46; Then we calculated the required information size &#40;RIS&#41;&#44; meaning the minimum sample size needed to detect the intervention effect of a 25&#37; relative risk reduction&#44; at a power of 80&#37;&#46;</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Results</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Literature search</span><p id="par0065" class="elsevierStylePara elsevierViewall">A total of 962 articles were retrieved&#44; and 833 articles remained after removing duplicates&#59; 753 irrelevant articles were removed after the title and abstract browsing&#46; After full-text reading of the remaining papers&#44; 9 meeting abstracts&#44; 2 incomplete outcome data&#44; 42 papers without background treatment with RAS blockers&#44; and 5 non-randomized controlled trials were excluded according to inclusion and exclusion criteria&#44; resulting in the inclusion of 10 papers that met the criteria&#46; The detailed literature screening process is shown in <a class="elsevierStyleCrossRef" href="#fig0025">Fig&#46; 1</a>&#46;</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Data extraction</span><p id="par0070" class="elsevierStylePara elsevierViewall">The 10 articles included are RCTs published from 2015 to 2020&#46; Both intervention and control groups were treated with RAS blockers as background&#44; and different types and doses of SGLT2is were used in the intervention group&#44; while the same dose of placebo was used in the control group&#46; Other necessary characteristics of the included literature are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Quality assessment</span><p id="par0075" class="elsevierStylePara elsevierViewall">Of the ten articles included&#44; only three did not explicitly account for random sequence generation and the remaining papers were low risk&#46; Three articles had high risk of selection bias and one was not mentioned&#46; For the double-blind experimental design&#44; only one paper did not use blinding&#44; and the rest of the literature described the double-blind design&#46; The outcome data from the six papers were all relatively complete and no significant gaps were found&#46; Reporting bias was unclear for five articles and other bias was unclear for six articles&#46; The detailed quality evaluation results are shown in <a class="elsevierStyleCrossRef" href="#sec0135">Fig&#46; A1 in appendix</a>&#46;</p><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Effects on cardiovascular death and heart failure-related hospitalization rates</span><p id="par0080" class="elsevierStylePara elsevierViewall">There are three studies on the effects of SGLT2 inhibitors in combination with RAS blockers on cardiovascular outcomes&#46; However&#44; no significant heterogeneity was observed between these studies&#44; and the analysis was performed using a fixed-effects model&#46; The results showed that the combination of SGLT2 inhibitors and RAS blockers significantly reduced the incidence of cardiovascular death &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;78&#44; 95&#37; CI&#58; 0&#46;66 to 0&#46;91&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;002&#44; <a class="elsevierStyleCrossRef" href="#fig0030">Fig&#46; 2</a>&#41; and the heart failure-related hospitalization rate &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;7&#44; 95&#37; CI&#58; 0&#46;61 to 0&#46;8&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#44; <a class="elsevierStyleCrossRef" href="#fig0030">Fig&#46; 2</a>&#41; in CKD patients&#46; These results suggest a protective role of SGLT2 inhibitors on cardiovascular outcomes and a significant cardiovascular benefit of using SGLT2 inhibitors with RAS blockers&#46;</p><elsevierMultimedia ident="fig0030"></elsevierMultimedia></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Effects on renal outcomes</span><p id="par0085" class="elsevierStylePara elsevierViewall">A total of 5 articles have reported the effects of SGLT2is in combination with RAS blockers on renal outcomes&#46; The incidence of progression to end-stage renal disease &#40;ESRD&#41; in the intervention group is less than that in the control group &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;69&#44; 95&#37; CI 0&#46;59&#8211;0&#46;81&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#44; <a class="elsevierStyleCrossRef" href="#fig0035">Fig&#46; 3</a>&#41;&#46; Pollock et al&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">17</span></a> and Perkovic et al&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">8</span></a> reported the effect of SGLT2is on creatinine elevation in the study subjects and found that the rate of creatinine elevation was significantly reduced in the SGLT2is group &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;61&#44; 95&#37; CI&#58; 0&#46;51&#8211;0&#46;74&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#44; <a class="elsevierStyleCrossRef" href="#fig0035">Fig&#46; 3</a>&#41;&#46;</p><elsevierMultimedia ident="fig0035"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">There were 2 studies mentioned the effects of two medicines combination on 24hUAE and other 3 about the change of eGFR&#46; And the results shown that the 24hUAE was significantly decreased after the intervention &#40;WMD<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#8722;0&#46;17&#44; 95&#37;CI &#8722;0&#46;18 to &#8722;0&#46;17&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#44; <a class="elsevierStyleCrossRef" href="#fig0040">Fig&#46; 4</a>&#41;&#46; Although it also decreased the estimated eGFR &#40;WMD<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#8722;5&#46;4&#44; 95&#37; CI&#58; &#8722;7&#46;24 to &#8722;3&#46;57&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#44; <a class="elsevierStyleCrossRef" href="#fig0040">Fig&#46; 4</a>&#41;&#44; this effect was reversible&#46;</p><elsevierMultimedia ident="fig0040"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">Renal-related adverse events and renal death have also been reported in four pieces of literature&#46; The results showed that there were no differences between the two groups in incidence of renal-related adverse events and renal death &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;83&#44; 95&#37;CI 0&#46;68&#8211;1&#46;01&#44; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;061&#59; RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;36&#44; 95&#37;CI 0&#46;12&#8211;1&#46;14&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;083&#44; <a class="elsevierStyleCrossRef" href="#fig0035">Fig&#46; 3</a>&#41;&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Effects on adverse events</span><p id="par0100" class="elsevierStylePara elsevierViewall">The effect of SGLT2 is on the incidence of adverse events was reported in six studies&#44; and there was no significant heterogeneity among them&#46; We found that the incidence of gential infection was increased &#40;RR&#61;3&#46;65&#44; 95&#37; CI 2&#46;68&#8211;4&#46;97&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#44; <a class="elsevierStyleCrossRef" href="#sec0135">Fig&#46; A2 in appendix</a>&#41;&#46; There were no significant changes in the incidence of hypoglycemia&#44; fractures&#44; urinary tract infection&#44; or volume depletion &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;431&#44; 0&#46;573&#44; 0&#46;849 and 0&#46;215&#44; respectively&#44; <a class="elsevierStyleCrossRef" href="#sec0135">Fig&#46; A2 in appendix</a>&#41;&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Effects on other parameters</span><p id="par0105" class="elsevierStylePara elsevierViewall">Only one study mentioned changes in N-terminal-pro hormone B-type natriuretic peptide &#40;NT-pro BNP&#41;&#44; and the results were not statistically significant&#46; Furthermore&#44; no change in the heart rate or diastolic blood pressure was observed during treatment compared with the placebo&#46;</p></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Reliability of cardiovascular outcomes result</span><p id="par0110" class="elsevierStylePara elsevierViewall">Our results indicated that the RIS of cardiovascular outcomes was 6874 samples&#46; The traditional boundary was the horizontal line at <span class="elsevierStyleItalic">Z</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1&#46;96&#44; which is considered to be the cut-off for statistical significance in the traditional sense&#46; And TSA threshold value was the boundary line obtained by correcting for type I error &#40;5&#37;&#41;&#46; Currently&#44; the cumulative <span class="elsevierStyleItalic">Z</span>-curve have crossed the traditional boundary and TSA threshold value &#40;<a class="elsevierStyleCrossRef" href="#sec0135">Fig&#46; A3&#44; A4 in appendix</a>&#41;&#44; which suggested that the result of the effects on cardiovascular outcomes was reliability&#46; What&#39;s more&#44; the cumulative <span class="elsevierStyleItalic">Z</span>-curve also have crossed the RIS&#44; indicating that the sample size was sufficient to account for the accuracy of the results obtained&#46;</p></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Discussion</span><p id="par0115" class="elsevierStylePara elsevierViewall">This meta-analysis included clinical studies reporting on the effects of SGLT2 inhibitors on CKD patients treated in combination with background therapy with RAS blockers&#46; The results proved that this treatment regimen could reduce the incidence of cardiovascular death and heart failure-related hospitalizations in CKD patients with or without diabetes while reducing the 24hUAE and delaying progression to ESRD&#46; Although eGFR decreased during treatment&#44; it was reversible after treatment discontinuation&#46; Furthermore&#44; on combining the two medicines&#44; except for the increase in genital infections&#44; the incidence of other adverse effects such as renal adverse effects and urinary tract infections did not increase significantly&#46; Therefore&#44; we reasonably deduced that the combined use of these agents could help improve the cardiovascular and renal prognosis in CKD patients&#46; Furthermore&#44; these data may help improve CKD-related guidelines&#44; and benefit these patients&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Cardiovascular events are a significant cause of death in patients with CKD&#44; especially in diabetes patients with CKD&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">23</span></a> Although RAS blockers are recommended as first-line treatment for CKD&#44;<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">4</span></a> they insufficiently reduce cardiovascular events&#46; A meta-analysis showed that SGLT2 inhibitors significantly reduced the incidence of cardiovascular events in diabetes patients&#44;<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">24&#44;25</span></a> further&#44; SGLT2 inhibitors have been recommended for use in diabetic diabetes patients with kidney diseases by the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">9</span></a> However&#44; studies have suggested that the cardiovascular and renal benefits of SGLT2 inhibitors may be independent of its hypoglycemic effect&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">26</span></a> Therefore&#44; the combined use of SGLT2 inhibitors&#44; and RAS blockers may have unprecedented efficacy in CKD patients&#44; but there is not enough evidence supporting it&#46; Our meta-analysis used RAS blockers as background treatment&#44; focusing on patients with CKD&#44; including diabetic nephropathy&#44; immunoglobulin A nephropathy &#40;IgAN&#41;&#44; and focal segmental glomerulosclerosis &#40;FSGS&#41;&#46; Results showed that SGLT2 inhibitors combined with RAS blockers could also reduce cardiovascular mortality and heart failure-related hospitalization rates in CKD patients&#46; The present meta-analysis filled the gaps in evidence and provided a basis for the combination of two medicines for CKD&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">In terms of renal outcomes&#44; we also observed that the combined use of SGLT2 inhibitors and RAS blockers delayed progression to ESRD&#44; decreased the 24hUAE and improved renal function&#59; furthermore&#44; the study population was not limited to diabetes patients with CKD&#46; Furthermore&#44; both DAPA-CKD and DIAMOND trails included IgAN and FSGS patients diagnosed with CKD&#46; Although no subgroup analysis was conducted for these patients&#44; the results can prove to a certain extent that SGLT2 inhibitors combined with RAS blockers have a good effect on IgAN and FSGS&#46; Similarly&#44; Hiddo et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">12</span></a> and Cherney et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">16</span></a> have reported that SGLT2 inhibitors delayed renal disease progression and reduced the risk of renal complex outcomes in CKD with or without diabetes&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">Several studies can explain the protective effect of this combination on the kidneys&#46; SGLT2 inhibitors increase the excretion of sodium and glucose in the proximal tubules&#46; Further&#44; they lead to the vasoconstriction of renal inflow arterioles via glomerular feedback&#44; relieve glomerular hyperperfusion and hyperfiltration&#44; and play a renal protection effect&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">27</span></a> Further&#44; the addition of RAS blockers has a better effect on delaying renal disease progression&#44; which may be associated with the diastolic effect of RAS on the glomerular arterioles of the kidney and the further reduction of renal pressure in the glomerulus&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">28</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">It is noteworthy that the mechanisms of SGLT2 inhibitors and RAS blockers respective effects on the heart and kidney are synergistic in many ways&#46; For example&#44; they regulate blood pressure through neurological and humoral pathways&#44; thereby improving the cardiovascular function&#46;<a class="elsevierStyleCrossRefs" href="#bib0315"><span class="elsevierStyleSup">29&#44;30</span></a> Furthermore&#44; they are synergistic in reducing inflammatory and oxidative stress in the renal tissue&#46;<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">27&#44;31&#8211;33</span></a> Previously&#44; RAS blockers were thought to be the only drugs used to prevent renal failure in CKD patients&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">33</span></a> Our study demonstrates that the combination of SGLT2 inhibitors and RAS blockers allows this effect to be superimposed and more effective&#46; However&#44; it should be noted that the baseline eGFRs of the subjects were<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#44; and the safety of SGLT2 inhibitors in CKD patients with eGFR<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> remains to be evaluated&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Although SGLT2 inhibitors have cardiovascular and renal benefits when combined with RAS blockers&#44; their safety profile needs to be considered&#46; This meta-analysis showed that the incidence of genital infections increased after SGLT2 inhibitor intervention&#44; and there was no significant difference in the incidence of hypoglycemia&#44; fractures&#44; and urinary tract infections between the two groups&#46; Our results are generally consistent with previous studies&#46;<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">26&#44;34</span></a> Therefore&#44; based on the current results&#44; the clinical use of SGLT2 inhibitors has a broad safety profile with few adverse effects&#46;</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Limitations</span><p id="par0145" class="elsevierStylePara elsevierViewall">First&#44; two of the included studies used canagliflozin and four used dapagliflozin&#59; this may cause some heterogeneity in the results because of the use of different medicines between studies&#46; Second&#44; fewer clinical indicators of renal function were included in this study&#44; including only 24hUAE and eGFR&#46; Third&#44; we included CKD patients with eGFRs<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#59; accordingly&#44; it is unclear whether the same results would be obtained in patients with eGFRs less than 30<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#44; and further clinical studies are needed to evalute this&#46;</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Conclusion</span><p id="par0150" class="elsevierStylePara elsevierViewall">These data provide a well-document testimonial of the benefits of the combined use of SGLT2 inhibitors and RAS blockers for cardiovascular and renal outcomes in CKD patients&#46;</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Authors&#8217; contributions</span><p id="par0155" class="elsevierStylePara elsevierViewall">TL&#44; RL and XW contributed equally to this work&#46; TL&#44; RL and XW conceived and designed the study&#46; RL and XW contributed to the literature search&#44; data extraction&#44; risk-of-bias assessment&#44; and article writing&#46; TL resolved the inconsistencies between reviewers&#46; XW&#44; RL and XG analyzed the data&#46; TL and XZ were responsible for revision of this manuscript for important intellectual content&#46; All authors read and approved the final manuscript&#46;</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Funding</span><p id="par0160" class="elsevierStylePara elsevierViewall">The meta-analysis research funding was supported by &#91;<span class="elsevierStyleGrantSponsor" id="gs1">International Cooperation of Shanxi Science and Technology</span>&#93; &#40;Fund number&#58; <span class="elsevierStyleGrantNumber" refid="gs1">201803D421063</span>&#41;&#46;</p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Conflict of interest</span><p id="par0165" class="elsevierStylePara elsevierViewall">There was no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres1744714"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Background and objective"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1537462"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1744713"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Antecedentes y objetivos"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "M&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1537461"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Methods"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Search strategy"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Inclusion and exclusion criteria"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Literature screening and data extraction"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Quality assessment"
            ]
            4 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Statistical analysis"
            ]
            5 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Trials sequential analysis &#40;TSA&#41;"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0045"
          "titulo" => "Results"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Literature search"
            ]
            1 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Data extraction"
            ]
            2 => array:3 [
              "identificador" => "sec0060"
              "titulo" => "Quality assessment"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0070"
                  "titulo" => "Effects on cardiovascular death and heart failure-related hospitalization rates"
                ]
                1 => array:2 [
                  "identificador" => "sec0075"
                  "titulo" => "Effects on renal outcomes"
                ]
                2 => array:2 [
                  "identificador" => "sec0080"
                  "titulo" => "Effects on adverse events"
                ]
                3 => array:2 [
                  "identificador" => "sec0085"
                  "titulo" => "Effects on other parameters"
                ]
              ]
            ]
            3 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Reliability of cardiovascular outcomes result"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Limitations"
        ]
        9 => array:2 [
          "identificador" => "sec0105"
          "titulo" => "Conclusion"
        ]
        10 => array:2 [
          "identificador" => "sec0110"
          "titulo" => "Authors&#8217; contributions"
        ]
        11 => array:2 [
          "identificador" => "sec0115"
          "titulo" => "Funding"
        ]
        12 => array:2 [
          "identificador" => "sec0120"
          "titulo" => "Conflict of interest"
        ]
        13 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2021-04-08"
    "fechaAceptado" => "2021-09-02"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1537462"
          "palabras" => array:5 [
            0 => "Sodium-glucose co-transporter 2 inhibitors"
            1 => "RAS blockers"
            2 => "Cardiovascular outcomes"
            3 => "Chronic kidney disease"
            4 => "Meta-analysis"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1537461"
          "palabras" => array:5 [
            0 => "Inhibidores del cotransportador de sodio-glucosa 2"
            1 => "Bloqueadores del SRA"
            2 => "Resultados cardiovasculares"
            3 => "Enfermedad renal cr&#243;nica"
            4 => "Metaan&#225;lisis"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background and objective</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Efficacy of sodium-glucose cotransporter 2 &#40;SGLT2&#41; inhibitors in combination with renin&#8211;angiotensin-system &#40;RAS&#41; blockers for CKD remains controversial&#46; We conducted this meta-analysis to explore the effect of SGLT2 inhibitors combining with RAS blockers on cardiovascular outcomes in chronic kidney disease &#40;CKD&#41; patients&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">We searched Embase&#44; PubMed&#44; Web of Science&#44; and Cochrane Library databases with the following keywords&#46;</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#8220;Renal Insufficiency&#44; Chronic&#8221; or &#8220;Diabetic Nephropathies&#8221; and &#8220;Sodium-glucose cotransporter 2 inhibitors&#8221;&#46; We included randomized controlled trials &#40;RCTs&#41; based on angiotensin-converting enzyme inhibitor &#40;ACEI&#41; or angiotensin II receptor blocker &#40;ARB&#41; therapy&#46; The outcome events included cardiac and renal outcomes and other adverse events&#46; This study is registered with PROSPERO&#58; CRD42020218337&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Ten RCTs including 16&#44;983 CKD patients met the inclusion criteria&#46; Compared with placebo plus RAS blockers&#44; SGLT2 inhibitors plus RAS blockers significantly reduced cardiovascular mortality and heart failure-related hospitalization rates &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;78&#44; 95&#37; CI&#58; 0&#46;66&#8211;0&#46;91&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;002&#59; RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;7&#44; 95&#37; CI&#58; 0&#46;61&#8211;0&#46;8&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#41;&#46; We also performed trials sequential analysis &#40;TSA&#41; and the results indicated that our results are reliable&#46; Additionally&#44; it significantly reduced the 24-h urinary albumin excretion rate &#40;24hUAE&#41; and the creatinine elevation rate &#40;WMD<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#8722;0&#46;19&#44; 95&#37; CI&#58; &#8722;0&#46;24 to &#8722;0&#46;14&#59; RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;61&#44; 95&#37; CI&#58; 0&#46;51&#8211;0&#46;74&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#41;&#44; delayed progression to end-stage renal disease &#40;ESRD&#41; &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;69&#44; 95&#37; CI&#58; 0&#46;59&#8211;0&#46;81&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;000&#41;&#46; Further&#44; it had no significant effect on the incidence of renal-related adverse events or renal-related mortality&#46; Although it decreased the estimated glomerular filtration rate &#40;eGFR&#41; &#40;WMD<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#8722;5&#46;4&#44; 95&#37; CI&#58; &#8722;7&#46;24 to &#8722;3&#46;57&#41;&#44; this effect was reversible&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">These data provide a well-document testimonial of the benefits of the combined use of SGLT2 inhibitors and RAS blockers for cardiovascular and renal outcomes in CKD patients&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Background and objective"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Antecedentes y objetivos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">La eficacia de los inhibidores del cotransportador de sodio-glucosa 2 &#40;SGLT2&#41; en combinaci&#243;n con los bloqueadores del sistema renina-angiotensina &#40;SRA&#41; para la enfermedad renal cr&#243;nica &#40;ERC&#41; sigue siendo controvertida&#46; Se realiz&#243; este metaan&#225;lisis para explorar el efecto de los inhibidores del SGLT2 en combinaci&#243;n con los bloqueadores del SRA sobre los resultados cardiovasculares en los pacientes con ERC&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">M&#233;todos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Se realizaron b&#250;squedas en las bases de datos Embase&#44; PubMed&#44; Web of Science y Cochrane Library con las siguientes palabras clave&#58; &#171;Renal Insufficiency&#44; Chronic&#187; o &#171;Diabetic Nephropathies&#187; y &#171;Sodium-glucose cotransporter 2 inhibitors&#187;&#46; Se incluyeron ensayos controlados aleatorios &#40;ECA&#41; basados en el tratamiento con inhibidores de la enzima convertidora de angiotensina &#40;IECA&#41; o bloqueadores de los receptores de la angiotensina II &#40;BRA&#41;&#46; Los eventos de resultado incluyeron resultados card&#237;acos y renales y otros eventos adversos&#46; Este estudio est&#225; registrado en PROSPERO&#58; CRD42020218337&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Diez ECA que inclu&#237;an 16&#46;983 pacientes con ERC cumplieron los criterios de inclusi&#243;n&#46; En comparaci&#243;n con el placebo m&#225;s bloqueadores del SRA&#44; los inhibidores de SGLT2 m&#225;s bloqueadores del SRA redujeron significativamente la mortalidad cardiovascular y las tasas de hospitalizaci&#243;n relacionadas con la insuficiencia card&#237;aca &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;78&#59; IC del 95&#37;&#58; 0&#44;66 a 0&#44;91&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;002&#59; RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;7&#59; IC del 95&#37;&#58; 0&#44;61 a 0&#44;8&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;000&#41;&#46; Tambi&#233;n se realiz&#243; un an&#225;lisis secuencial de ensayos &#40;TSA&#41; y los resultados indicaron que nuestros resultados son fiables&#46; Adem&#225;s&#44; redujo significativamente la tasa de excreci&#243;n urinaria de alb&#250;mina en 24<span class="elsevierStyleHsp" style=""></span>h &#40;24<span class="elsevierStyleHsp" style=""></span>h UAE&#41; y la tasa de elevaci&#243;n de creatinina &#40;DMP<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#8722;0&#44;19&#59; IC del 95&#37;&#58; &#8722;0&#44;24 a &#8722;0&#44;14&#59; RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;61&#59; IC del 95&#37;&#58; 0&#44;51 a 0&#44;74&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;000&#41;&#44; retras&#243; la progresi&#243;n a la enfermedad renal terminal &#40;ESRD&#41; &#40;RR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;69&#59; IC del 95&#37;&#58; 0&#44;59 a 0&#44;81&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;000&#41;&#46; Adem&#225;s&#44; no tuvo un efecto significativo sobre la incidencia de eventos adversos relacionados con el ri&#241;&#243;n o la mortalidad relacionada con el ri&#241;&#243;n&#46; Aunque disminuy&#243; la tasa de filtraci&#243;n glomerular estimada &#40;TFGe&#41; &#40;DMP<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#8722;5&#44;4&#59; IC del 95&#37;&#58; &#8722;7&#44;24 a &#8722;3&#44;57&#41;&#44; este efecto fue reversible&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Estos datos proporcionan un testimonio bien documentado de los beneficios del uso combinado de inhibidores de SGLT2 y bloqueadores del SRA para los resultados cardiovasculares y renales en pacientes con ERC&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Antecedentes y objetivos"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "M&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "1"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Ting Liu&#44; Rui Li and Xiaoxia Wang contributed equally to this paper&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0180" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Supplementary data"
            "identificador" => "sec0135"
          ]
        ]
      ]
    ]
    "multimedia" => array:9 [
      0 => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2737
            "Ancho" => 2925
            "Tamanyo" => 419315
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Flow diagram of study screening&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0030"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1549
            "Ancho" => 2083
            "Tamanyo" => 173990
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Forest plot of meta-analyses comparing cardiovascular death and heart failure hospitalization rates of combination therapy with SGLT2 inhibitors and RAS blockers versus placebo&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0035"
        "etiqueta" => "Fig&#46; 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1860
            "Ancho" => 2175
            "Tamanyo" => 244414
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Forest plot of meta-analyses comparing renal outcomes of combination therapy with SGLT2 inhibitors and RAS blockers versus placebo&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0040"
        "etiqueta" => "Fig&#46; 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1614
            "Ancho" => 2175
            "Tamanyo" => 175853
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Forest plot of meta-analyses comparing 24hUAE and eGFR of combination therapy with SGLT2 inhibitors and RAS blockers versus placebo&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Study&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Mean age &#40;years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Mean aseline eGFR &#40;ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Sample size&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Interventions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Follow-up&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Intervention Concorl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Intervention Concorl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Heerspink<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">12</span></a> 2020&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">With or without type 2 diabetes&#44; GFR of 25&#8211;75<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1425 &#40;33&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">61&#46;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">43&#46;2<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#46;343&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21522152&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">dapagliflozin &#40;10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;4 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cherney<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">16</span></a> 2020&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CKD 24<span class="elsevierStyleHsp" style=""></span>h urinary protein excretion 500&#8211;3500<span class="elsevierStyleHsp" style=""></span>mg and eGFR &#62;25<span class="elsevierStyleHsp" style=""></span>mL&#47;min per 1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;32&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#46;8 &#40;25&#46;5&#41;58&#46;9 &#40;20&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2627&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">dapagliflozin &#40;10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pollock<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">17</span></a> 2019&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes and moderate to severe chronic kidney disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">86 &#40;59&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">64&#46;7 &#40;8&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;2 &#40;13&#46;0&#41;47&#46;7 &#40;13&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">145148&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">dapagliflozin &#40;10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Perkovic<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">8</span></a> 2019&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes with chronic kidney disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1494 &#40;33&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>9&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56&#46;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>18&#46;256&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>18&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22022199&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">canagliflozin &#40;100<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;62 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Triantafylidis<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">18</span></a> 2019&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diabetic kidney disease albumin&#58;creatinine ratio<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>300<span class="elsevierStyleHsp" style=""></span>mg&#47;g&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67 <span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1414&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">empagliflozin &#40;10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Wanner<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">9</span></a> 2018&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes with nephropathy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2004 &#40;28&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46852333&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">empagliflozin &#40;10&#47;25<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Petrykiv<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">19</span></a> 2017&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes and albumin&#58;creatinine ratio<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>100<span class="elsevierStyleHsp" style=""></span>mg&#47;g&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;24&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">61<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">72 &#40;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">dapagliflozin &#40;10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Wanner<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">20</span></a> 2016&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes with nephropathy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2004 &#40;28&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46852333&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">empagliflozin &#40;10&#47;25<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">David Cherney<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">21</span></a> 2016&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes with microalbuminuria and ma croalbuminuria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">337 &#40;39&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">516335&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">empagliflozin &#40;10&#47;25<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Zinman<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">22</span></a> 2015&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Type 2 diabetes with kidney disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2004 &#40;28&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46872333&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">empagliflozin &#40;10&#47;25<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Basic characteristic of included study&#46;</p>"
        ]
      ]
      5 => array:5 [
        "identificador" => "fig0005"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "mmc1.jpeg"
            "Alto" => 1672
            "Ancho" => 2167
            "Tamanyo" => 248903
          ]
        ]
      ]
      6 => array:5 [
        "identificador" => "fig0010"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "mmc2.jpeg"
            "Alto" => 2409
            "Ancho" => 2333
            "Tamanyo" => 449824
          ]
        ]
      ]
      7 => array:5 [
        "identificador" => "fig0015"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "mmc3.jpeg"
            "Alto" => 1766
            "Ancho" => 2175
            "Tamanyo" => 166871
          ]
        ]
      ]
      8 => array:5 [
        "identificador" => "fig0020"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "mmc4.jpeg"
            "Alto" => 1783
            "Ancho" => 2175
            "Tamanyo" => 174795
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:34 [
            0 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic kidney disease&#58; global dimension and perspectives"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Jha"
                            1 => "G&#46; Garcia-Garcia"
                            2 => "K&#46; Iseki"
                            3 => "Z&#46; Li"
                            4 => "S&#46; Naicker"
                            5 => "B&#46; Plattner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet &#40;Lond&#44; Engl&#41;"
                        "fecha" => "2013"
                        "volumen" => "382"
                        "paginaInicial" => "260"
                        "paginaFinal" => "272"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic kidney disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;C&#46; Webster"
                            1 => "E&#46;V&#46; Nagler"
                            2 => "R&#46;L&#46; Morton"
                            3 => "P&#46; Masson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet &#40;Lond&#44; Engl&#41;"
                        "fecha" => "2017"
                        "volumen" => "389"
                        "paginaInicial" => "1238"
                        "paginaFinal" => "1252"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cause of death in patients with reduced kidney function"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Thompson"
                            1 => "M&#46; James"
                            2 => "N&#46; Wiebe"
                            3 => "B&#46; Hemmelgarn"
                            4 => "B&#46; Manns"
                            5 => "S&#46; Klarenbach"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1681/ASN.2014070714"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Soc Nephrol"
                        "fecha" => "2015"
                        "volumen" => "26"
                        "paginaInicial" => "2504"
                        "paginaFinal" => "2511"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25733525"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of renin&#8211;angiotensin system blockade in advanced CKD&#58; an NKF-KDOQI controversies report"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;R&#46; Weir"
                            1 => "J&#46;I&#46; Lakkis"
                            2 => "B&#46; Jaar"
                            3 => "M&#46;V&#46; Rocco"
                            4 => "M&#46;J&#46; Choi"
                            5 => "H&#46;J&#46; Kramer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.ajkd.2018.06.010"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Kidney Dis"
                        "fecha" => "2018"
                        "volumen" => "72"
                        "paginaInicial" => "873"
                        "paginaFinal" => "884"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30201547"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality&#58; a Taiwanese Nationwide cohort study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;F&#46; Lee"
                            1 => "L&#46;C&#46; See"
                            2 => "Y&#46;H&#46; Chan"
                            3 => "Y&#46;H&#46; Yeh"
                            4 => "L&#46;S&#46; Wu"
                            5 => "J&#46;R&#46; Liu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/imj.13971"
                      "Revista" => array:6 [
                        "tituloSerie" => "Intern Med J"
                        "fecha" => "2018"
                        "volumen" => "48"
                        "paginaInicial" => "1123"
                        "paginaFinal" => "1132"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29808610"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Probing SGLT2 as a therapeutic target for diabetes&#58; basic physiology and consequences"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "L&#46;A&#46; Gallo"
                            1 => "E&#46;M&#46; Wright"
                            2 => "V&#46; Vallon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1479164114561992"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diab Vasc Dis Res"
                        "fecha" => "2015"
                        "volumen" => "12"
                        "paginaInicial" => "78"
                        "paginaFinal" => "89"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25616707"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Contribution of the kidney to glucose homeostasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46; Segura"
                            1 => "L&#46;M&#46; Ruilope"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Med Clin"
                        "fecha" => "2013"
                        "volumen" => "141"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "26"
                        "paginaFinal" => "30"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Perkovic"
                            1 => "M&#46;J&#46; Jardine"
                            2 => "B&#46; Neal"
                            3 => "S&#46; Bompoint"
                            4 => "H&#46;J&#46;L&#46; Heerspink"
                            5 => "D&#46;M&#46; Charytan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1811744"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2019"
                        "volumen" => "380"
                        "paginaInicial" => "2295"
                        "paginaFinal" => "2306"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30990260"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus&#46; Established cardiovascular disease&#44; and chronic kidney disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Wanner"
                            1 => "J&#46;M&#46; Lachin"
                            2 => "S&#46;E&#46; Inzucchi"
                            3 => "D&#46; Fitchett"
                            4 => "M&#46; Mattheus"
                            5 => "J&#46; George"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.117.028268"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2018"
                        "volumen" => "137"
                        "paginaInicial" => "119"
                        "paginaFinal" => "129"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28904068"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diabetes management in chronic kidney disease&#58; synopsis of the 2020 KDIGO clinical practice guideline"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Navaneethan"
                            1 => "S&#46; Zoungas"
                            2 => "M&#46;L&#46; Caramori"
                            3 => "J&#46;C&#46;N&#46; Chan"
                            4 => "H&#46;J&#46;L&#46; Heerspink"
                            5 => "C&#46; Hurst"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The role of sodium glucose cotransporter-2 &#40;SGLT-2&#41; inhibitors in heart failure and chronic kidney disease in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "V&#46; Woo"
                            1 => "K&#46; Connelly"
                            2 => "P&#46; Lin"
                            3 => "P&#46; McFarlane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/03007995.2019.1576479"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Med Res Opin"
                        "fecha" => "2019"
                        "volumen" => "35"
                        "paginaInicial" => "1283"
                        "paginaFinal" => "1295"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30767677"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dapagliflozin in patients with chronic kidney disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;J&#46;L&#46; Heerspink"
                            1 => "B&#46;V&#46; Stef&#225;nsson"
                            2 => "R&#46; Correa-Rotter"
                            3 => "G&#46;M&#46; Chertow"
                            4 => "T&#46; Greene"
                            5 => "F&#46;F&#46; Hou"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa2024816"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2020"
                        "volumen" => "383"
                        "paginaInicial" => "1436"
                        "paginaFinal" => "1446"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32970396"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Back to the future&#58; glomerular hyperfiltration and the diabetic kidney"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "K&#46;R&#46; Tuttle"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2337/dbi16-0056"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetes"
                        "fecha" => "2017"
                        "volumen" => "66"
                        "paginaInicial" => "14"
                        "paginaFinal" => "16"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27999101"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions&#58; explanation and elaboration"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Liberati"
                            1 => "D&#46;G&#46; Altman"
                            2 => "J&#46; Tetzlaff"
                            3 => "C&#46; Mulrow"
                            4 => "P&#46;C&#46; G&#248;tzsche"
                            5 => "J&#46;P&#46; Ioannidis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "PLoS Med"
                        "fecha" => "2009"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Meta-analysis of observational studies in epidemiology&#58; a proposal for reporting&#46; Meta-analysis Of Observational Studies in Epidemiology &#40;MOOSE&#41; group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;F&#46; Stroup"
                            1 => "J&#46;A&#46; Berlin"
                            2 => "S&#46;C&#46; Morton"
                            3 => "I&#46; Olkin"
                            4 => "G&#46;D&#46; Williamson"
                            5 => "D&#46; Rennie"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.283.15.2008"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2000"
                        "volumen" => "283"
                        "paginaInicial" => "2008"
                        "paginaFinal" => "2012"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10789670"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease &#40;DIAMOND&#41;&#58; a randomised&#44; double-blind&#44; crossover trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;Z&#46;I&#46; Cherney"
                            1 => "C&#46;C&#46;J&#46; Dekkers"
                            2 => "S&#46;J&#46; Barbour"
                            3 => "D&#46; Cattran"
                            4 => "A&#46;H&#46; Abdul Gafor"
                            5 => "P&#46;J&#46; Greasley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet Diab Endocrinol"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "582"
                        "paginaFinal" => "593"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease &#40;DELIGHT&#41;&#58; a randomised&#44; double-blind&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Pollock"
                            1 => "B&#46; Stef&#225;nsson"
                            2 => "D&#46; Reyner"
                            3 => "P&#46; Rossing"
                            4 => "C&#46;D&#46; Sj&#246;str&#246;m"
                            5 => "D&#46;C&#46; Wheeler"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet Diab Endocrinol"
                        "fecha" => "2019"
                        "volumen" => "7"
                        "paginaInicial" => "429"
                        "paginaFinal" => "441"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A pilot study embedding clinical pharmacists within an interprofessional nephrology clinic for the initiation and monitoring of empagliflozin in diabetic kidney disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "L&#46;K&#46; Triantafylidis"
                            1 => "C&#46;E&#46; Hawley"
                            2 => "C&#46; Fagbote"
                            3 => "J&#46; Li"
                            4 => "N&#46; Genovese"
                            5 => "J&#46;M&#46; Paik"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "J Pharm Pract"
                        "fecha" => "2019"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46;I&#46; Petrykiv"
                            1 => "G&#46;D&#46; Laverman"
                            2 => "D&#46; de Zeeuw"
                            3 => "H&#46;J&#46;L&#46; Heerspink"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Diab Obes Metab"
                        "fecha" => "2017"
                        "volumen" => "19"
                        "paginaInicial" => "1363"
                        "paginaFinal" => "1370"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Empagliflozin and progression of kidney disease in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Wanner"
                            1 => "S&#46;E&#46; Inzucchi"
                            2 => "J&#46;M&#46; Lachin"
                            3 => "D&#46; Fitchett"
                            4 => "M&#46; von Eynatten"
                            5 => "M&#46; Mattheus"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2016"
                        "volumen" => "375"
                        "paginaInicial" => "323"
                        "paginaFinal" => "334"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Cherney"
                            1 => "S&#46;S&#46; Lund"
                            2 => "B&#46;A&#46; Perkins"
                            3 => "P&#46;H&#46; Groop"
                            4 => "M&#46;E&#46; Cooper"
                            5 => "S&#46; Kaspers"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00125-016-4008-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetologia"
                        "fecha" => "2016"
                        "volumen" => "59"
                        "paginaInicial" => "1860"
                        "paginaFinal" => "1870"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27316632"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Empagliflozin&#44; cardiovascular outcomes&#44; and mortality in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Zinman"
                            1 => "C&#46; Wanner"
                            2 => "J&#46;M&#46; Lachin"
                            3 => "D&#46; Fitchett"
                            4 => "E&#46; Bluhmki"
                            5 => "S&#46; Hantel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1504720"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "2117"
                        "paginaFinal" => "2128"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26378978"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Kidney disease and increased mortality risk in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Afkarian"
                            1 => "M&#46;C&#46; Sachs"
                            2 => "B&#46; Kestenbaum"
                            3 => "I&#46;B&#46; Hirsch"
                            4 => "K&#46;R&#46; Tuttle"
                            5 => "J&#46; Himmelfarb"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1681/ASN.2012070718"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Soc Nephrol"
                        "fecha" => "2013"
                        "volumen" => "24"
                        "paginaInicial" => "302"
                        "paginaFinal" => "308"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23362314"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46;L&#46; Neuen"
                            1 => "T&#46; Young"
                            2 => "H&#46;J&#46;L&#46; Heerspink"
                            3 => "B&#46; Neal"
                            4 => "V&#46; Perkovic"
                            5 => "L&#46; Billot"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet Diab Endocrinol"
                        "fecha" => "2019"
                        "volumen" => "7"
                        "paginaInicial" => "845"
                        "paginaFinal" => "854"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SGLT2 inhibitors in patients with heart failure with reduced ejection fraction&#58; a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Zannad"
                            1 => "J&#46;P&#46; Ferreira"
                            2 => "S&#46;J&#46; Pocock"
                            3 => "S&#46;D&#46; Anker"
                            4 => "J&#46; Butler"
                            5 => "G&#46; Filippatos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet &#40;Lond&#44; Engl&#41;"
                        "fecha" => "2020"
                        "volumen" => "396"
                        "paginaInicial" => "819"
                        "paginaFinal" => "829"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;C&#46; Petrie"
                            1 => "S&#46; Verma"
                            2 => "K&#46;F&#46; Docherty"
                            3 => "S&#46;E&#46; Inzucchi"
                            4 => "I&#46; Anand"
                            5 => "J&#46; Belohl&#225;vek"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.2020.1906"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2020"
                        "volumen" => "323"
                        "paginaInicial" => "1353"
                        "paginaFinal" => "1368"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32219386"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Vallon"
                            1 => "M&#46; Gerasimova"
                            2 => "M&#46;A&#46; Rose"
                            3 => "T&#46; Masuda"
                            4 => "J&#46; Satriano"
                            5 => "E&#46; Mayoux"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Am J Physiol Renal Physiol"
                        "fecha" => "2014"
                        "volumen" => "306"
                        "paginaInicial" => "F194"
                        "paginaFinal" => "F204"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Glomerular hemodynamics in experimental diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "T&#46;H&#46; Hostetter"
                            1 => "J&#46;L&#46; Troy"
                            2 => "B&#46;M&#46; Brenner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ki.1981.33"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "1981"
                        "volumen" => "19"
                        "paginaInicial" => "410"
                        "paginaFinal" => "415"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7241881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes&#58; updated systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "X&#46; Xie"
                            1 => "E&#46; Atkins"
                            2 => "J&#46; Lv"
                            3 => "A&#46; Bennett"
                            4 => "B&#46; Neal"
                            5 => "T&#46; Ninomiya"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet &#40;Lond&#44; Engl&#41;"
                        "fecha" => "2016"
                        "volumen" => "387"
                        "paginaInicial" => "435"
                        "paginaFinal" => "443"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus &#40;the ADVANCE trial&#41;&#58; a randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Patel"
                            1 => "S&#46; MacMahon"
                            2 => "J&#46; Chalmers"
                            3 => "B&#46; Neal"
                            4 => "M&#46; Woodward"
                            5 => "L&#46; Billot"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet &#40;Lond&#44; Engl&#41;"
                        "fecha" => "2007"
                        "volumen" => "370"
                        "paginaInicial" => "829"
                        "paginaFinal" => "840"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characterization and comparison of SGLT2 inhibitors&#58; Part 3 Effects on diabetic complications in type 2 diabetic mice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Tahara"
                            1 => "T&#46; Takasu"
                            2 => "M&#46; Yokono"
                            3 => "M&#46; Imamura"
                            4 => "E&#46; Kurosaki"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejphar.2017.05.019"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Pharmacol"
                        "fecha" => "2017"
                        "volumen" => "809"
                        "paginaInicial" => "163"
                        "paginaFinal" => "171"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28506912"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Canagliflozin reduces inflammation and fibrosis biomarkers&#58; a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;J&#46;L&#46; Heerspink"
                            1 => "P&#46; Perco"
                            2 => "S&#46; Mulder"
                            3 => "J&#46; Leierer"
                            4 => "M&#46;K&#46; Hansen"
                            5 => "A&#46; Heinzel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00125-019-4859-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetologia"
                        "fecha" => "2019"
                        "volumen" => "62"
                        "paginaInicial" => "1154"
                        "paginaFinal" => "1166"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31001673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Ruggenenti"
                            1 => "A&#46; Perna"
                            2 => "G&#46; Gherardi"
                            3 => "G&#46; Garini"
                            4 => "C&#46; Zoccali"
                            5 => "M&#46; Salvadori"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet &#40;Lond&#44; Engl&#41;"
                        "fecha" => "1999"
                        "volumen" => "354"
                        "paginaInicial" => "359"
                        "paginaFinal" => "364"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents&#58; implications for future treatment strategies in type 2 diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "G&#46; Schernthaner"
                            1 => "M&#46;H&#46; Schernthaner-Reiter"
                            2 => "G&#46;H&#46; Schernthaner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clinthera.2016.04.037"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Ther"
                        "fecha" => "2016"
                        "volumen" => "38"
                        "paginaInicial" => "1288"
                        "paginaFinal" => "1298"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27210264"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00257753/0000015900000002/v1_202207080542/S0025775321006473/v1_202207080542/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "93343"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00257753/0000015900000002/v1_202207080542/S0025775321006473/v1_202207080542/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321006473?idApp=UINPBA00004N"
]
Article information
ISSN: 00257753
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 March 1 1 2
2023 March 1 3 4
2023 February 0 2 2
2022 October 1 0 1
2022 August 1 2 3
2022 July 2 12 14
2022 May 0 2 2

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos